54 reports

GLOBALDATA EPIDEMIOLOGISTS CALCULATED THE ONE-, TWO-, THREE-, AND FOUR-YEAR OBSERVED SURVIVAL PERCENTAGES USING US WEIGHTS FROM 1990-2009.

  • Targeted Therapy
  • Market Size
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Roche Group

Persistent cough, shortness of breath, frequent chest infections, coughing up blood, pain or discomfort in the chest and weight loss.

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

AEs of Grade III or higher in the TS-## and UFT/ LV groups were diarrhea, loss of appetite, elevated total bilirubin value, elevated AST, and elevated ALT (Taiho Pharma, press release, January ##, 2013).

  • Chemotherapy
  • Targeted Therapy
  • Therapy
  • Market Size
  • Merck & Co., Inc.

PEOPLE SUFFERING FROM UC OFTEN EXPERIENCE LOSS OF APPETITE, FATIGUE, AND WEIGHT LOSS.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Remicade group

GISTs can be asymptomatic or present with various non-specific signs, depending on the location and size of tumor, such as loss of appetite, anemia, weight loss, fatigue, abdominal discomfort or fullness, nausea, vomiting, as well as an abdominal mass, blood in stool, and

  • Targeted Therapy
  • Market Size
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG

Fatigue, fever, and weight loss are also common RA symptoms. ##. ##. ## RHEUMATOID ARTHRITIS Stage one, or early-stage RA, involves initial inflammation in the joint capsule and swelling of synovial tissue.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson

COMMON SYMPTOMS OF CRC ARE: BLOOD IN STOOL, STOMACH PAINS, ACHES OR CRAMPS THAT DO NOT GO AWAY, WEIGHT LOSS, AND A PERSISTENT CHANGE IN BOWEL HABIT (CDC, 2016; NHS, 2015).

  • Targeted Therapy
  • Market Size
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

THIS IN TURN LEADS TO MALABSORPTION OF INGESTED FOOD, MALNUTRITION AND WEIGHT LOSS.

  • Targeted Therapy
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biologics, Inc.

Glucose levels and intraocular pressure are measured today, but just one measurement at a time in the doctor' s office.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC

Metastatic breast cancer has a variety of non-specific symptoms, such as unexplained weight loss, fever, chills, and bone pain.

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group

THESE SYMPTOMS CAN INCLUDE HEMOPTYSIS (COUGHING UP BLOOD), DYSPNEA (SHORTNESS OF BREATH), MALAISE, WEIGHT LOSS, AND HOARSENESS.

  • Targeted Therapy
  • Market Size
  • Eli Lilly & Co.
  • Novartis AG
  • Pfizer Inc.

A number of AEs occurred more frequently in the roflumilast treatment groups than in placebo groups, including diarrhea (##-##%), weight loss (##- ##%), and nausea (##%) (Bayer, 2012).

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Novartis AG

PROFILES OF HEALTH, AUSTRALIA, 2011-## - HEIGHT AND WEIGHT.

  • Targeted Therapy
  • Market Size
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group

Less common symptoms include weight loss, rheumatoid nodules and, rarely, inflammation in other organs and tissues, including the eyes, heart and lungs. ##. ## Symptoms Rheumatoid nodules are firm, fleshy, subcutaneous lumps that can appear on the hands, feet and elbows.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.

However, the effect of weight loss on the general risk of cancer among obese patients has been poorly characterized, as only a small proportion of obese persons are able to achieve sustained weight loss.

  • Targeted Therapy
  • Market Size
  • Celgene Corporation
  • Novartis AG
  • Pfizer Inc.

HOWEVER, MORE THAN ##% OF PATIENTS WILL EVENTUALLY PRESENT WITH HEMATURIA, AND A CONSIDERABLE NUMBER WILL HAVE SYSTEMIC SYMPTOMS SUCH AS ANAEMIA, FEVER, AND WEIGHT LOSS (LINEHAN ET AL., 2005).

  • Targeted Therapy
  • Market Size
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Pfizer Inc.

PEOPLE SUFFERING FROM UC OFTEN EXPERIENCE LOSS OF APPETITE, FATIGUE, AND WEIGHT LOSS.

  • Targeted Therapy
  • Market Size
  • EA Pharma Co., Ltd.
  • Pfizer Inc.
  • Remicade group

Provera, in the treatment of kidney cancer, can result in water retention, weight gain, indigestion and sleeplessness.

  • Targeted Therapy
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Pfizer Inc.

Indirect costs include unemployment, productivity loss, and losses due to disability.

  • Targeted Therapy
  • Market Size
  • Amgen Inc.
  • Pfizer Inc.
  • Remicade group

The most commonly reported AEs (affecting more than ##% of patients) in the Afinitor arm included stomatitis, rash, fatigue, diarrhea, nausea, decreased appetite, weight loss, and cough.

  • Targeted Therapy
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

GLOBALDATA ASSUMES AVERAGE COUNTRY-SPECIFIC WEIGHTS FOR A ##:## RATIO OF WOMEN TO MEN.

  • Targeted Therapy
  • World
  • Market Size
  • AstraZeneca PLC
  • Merck & Co., Inc.

FATIGUE, FEVER, AND WEIGHT LOSS ARE ALSO COMMON RA SYMPTOMS.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Remicade group

Appetite is often decreased during periods of disease exacerbation, leading to further weight loss.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

WEIGHT LOSS AND MALNUTRITION ARE COMMON SECONDARY TO DYSPHAGIA, BOTH OF WHICH CONTRIBUTE TO A POORER PATIENT PROGNOSIS.

  • Targeted Therapy
  • Market Size
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group

The BOLERO-## trial results reported that the most common AEs, affecting more than ##% of subjects, in the Afinitor treatment arm were stomatitis, rash, fatigue, diarrhea, nausea, decreased appetite, weight loss, and cough.

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Genentech, Inc.
  • Novartis AG

However, the effect of weight loss on the general risk of cancer among obese patients has been poorly characterized, as only a small proportion of obese persons are able to achieve sustained weight loss.

  • Targeted Therapy
  • Market Size
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.

Less common symptoms include weight loss, rheumatoid nodules and, rarely, inflammation in other organs and tissues, including the eyes, heart and lungs.

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Galapagos NV

The following symptoms are common among lung cancer patients: ##. ## Symptoms Chest pain Recurrent cough Coughing up blood Fatigue Weight loss Shortness of breath Smoking increases the chances of an individual developing NSCLC, although the root cause is a range of random mutations in

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group

OTHER SYMPTOMS MAY INCLUDE FEVER, WEIGHT LOSS AND POOR APPETITE, FATIGUE, ITCHY SKIN AND RASH.

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

MOST AES REPORTED IN THE PHASE III STUDIES WERE MILD TO MODERATE AND INCLUDED DIARRHEA, NAUSEA, UPPER RESPIRATORY TRACT INFECTION, WEIGHT LOSS, AND NASOPHARYNGITIS.

  • Targeted Therapy
  • World
  • Market Size
  • Amgen Inc.
  • Merck & Co., Inc.